Fidelity Investments’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-2,446,390
Closed -$9.59M 5770
2023
Q3
$9.59M Buy
2,446,390
+2,319,965
+1,835% +$15.8M ﹤0.01% 1838
2023
Q2
$411K Sell
126,425
-683,429
-84% -$2.03M ﹤0.01% 2720
2023
Q1
$2.93M Sell
809,854
-11,564
-1% -$179K ﹤0.01% 2263
2022
Q4
$26.4M Buy
821,418
+11,465
+1% +$454K ﹤0.01% 1503
2022
Q3
$33.9M Buy
809,953
+668
+0.1% +$30.5K ﹤0.01% 1401
2022
Q2
$34.2M Buy
809,285
+406,961
+101% +$18.9M ﹤0.01% 1427
2022
Q1
$27.3M Buy
402,324
+1,374
+0.3% +$114K ﹤0.01% 1647
2021
Q4
$48.7M Buy
400,950
+463
+0.1% +$78.2K ﹤0.01% 1431
2021
Q3
$56.4M Buy
400,487
+183
+0% +$36.3K ﹤0.01% 1362
2021
Q2
$110M Buy
400,304
+292
+0.1% +$73.7K 0.01% 1087
2021
Q1
$85.6M Buy
400,012
+59,844
+18% +$16.5M 0.01% 1137
2020
Q4
$82.3M Buy
340,168
+90,119
+36% +$11.1M 0.01% 1120
2020
Q3
$26.4M Buy
250,049
+22,488
+10% +$2.05M ﹤0.01% 1450
2020
Q2
$22.3M Buy
227,561
+66,518
+41% +$5.82M ﹤0.01% 1505
2020
Q1
$12.1M Sell
161,043
-1,078
-0.7% -$103K ﹤0.01% 1633
2019
Q4
$13.2M Sell
162,121
-3,377
-2% -$378K ﹤0.01% 1748
2019
Q3
$20.2M Sell
165,498
-2,885
-2% -$397K ﹤0.01% 1571
2019
Q2
$30.2M Buy
168,383
+2,128
+1% +$344K ﹤0.01% 1447
2019
Q1
$26.6M Buy
166,255
+955
+0.6% +$189K ﹤0.01% 1462
2018
Q4
$43M Buy
165,300
+2,055
+1% +$414K 0.01% 1210
2018
Q3
$38.6M Sell
163,245
-2,310
-1% -$605K ﹤0.01% 1394
2018
Q2
$36.8M Buy
+165,555
New +$48.3M ﹤0.01% 1430

Other funds holding EVLO

Fidelity Investments's EVLO Position: Q4 2023 in Review

Fidelity Investments sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 2,446,390 shares — an estimated $9.59M sold.

Fidelity Investments first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $110M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.

  • Fidelity Investments reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Fidelity Investments sold 2,446,390 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $9.59M.
  • Fidelity Investments first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
  • Fidelity Investments's Evelo Biosciences, Inc. Common Stock position peaked at $110M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.

Based on Fidelity Investments's 13F filing for Q4 2023, filed 13 Feb 2024.